Journey Medical Corporation Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

LICENSES ACQUIRED (Details)

LICENSES ACQUIRED (Details) $ in Thousands, ¥ in Billions					1 Months Ended						12 Months Ended
LICENSES ACQUIRED (Details) $ in Thousands, ¥ in Billions	Nov. 11, 2024 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2023 JPY (¥)	Jun. 29, 2021 USD ($)	Aug. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)	Jan. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Assets and Licenses Acquired
Total other revenues											$ 619	$ 1,000
Amzeeq
Assets and Licenses Acquired
Percentage of license								4.00%
Zilxi
Assets and Licenses Acquired
Percentage of license								1.50%
Emrosi Agreement
Assets and Licenses Acquired
Total Upfront payment				$ 10,000
Upfront payment upon execution							$ 3,000
Remaining upfront payment						$ 15,000
Transformation of ownership and all assets of milestone payments				15,000
Threshold additional contingent regulatory and commercial milestone payments payable				$ 150,000
Percentage of reduction in royalty upon launching of competitor products				50.00%
Emrosi Agreement \| Minimum
Assets and Licenses Acquired
Percentage of royalties payable on net sales				10.00%
Emrosi Agreement \| Maximum
Assets and Licenses Acquired
Percentage of royalties payable on net sales				14.00%
Asset purchase agreement \| Qbrexza
Assets and Licenses Acquired
Age of patients									9 years
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Period of royalty payments									2 years
Asset purchase agreement \| Minimum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments									30.00%
Asset purchase agreement \| Minimum \| Royalty payment percentage for eight years thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments									12.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments									40.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for eight years thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments									19.00%
Asset purchase agreement \| Eli Lilly and Company \| Qbrexza
Assets and Licenses Acquired
Upfront fees									$ 12,500
Milestone payments payable									$ 144,000
License and supply agreement With DRL \| Accutane
Assets and Licenses Acquired
Amount of expense paid under the agreement										$ 5,000
Contingent amount payable										$ 17,000
Term of accutane										10 years
Termination accutane agreement period										180 days
New License Agreement
Assets and Licenses Acquired
Total Upfront payment		$ 19,000
Amount of obligation payment terminated		10,000
Remaining obligation payments		$ 45,000
New License Agreement \| Net sales of at least ¥4 billion (yen)
Assets and Licenses Acquired
Net sales \| ¥			¥ 4
Cutia License Agreement
Assets and Licenses Acquired
Total other revenues												$ 1,000
Cutia License Agreement \| Amzeeq
Assets and Licenses Acquired
Milestone payment	$ 1,000
Total other revenues	$ 1,000				$ 600
VYNE APA
Assets and Licenses Acquired
Total Upfront payment								$ 450,000
Upfront payment upon execution								5,000
Upfront fees								20,000
VYNE APA \| Amzeeq \| First year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								10,000
Net sales								100,000
VYNE APA \| Amzeeq \| Second year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								20,000
Net sales								200,000
VYNE APA \| Amzeeq \| Third year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								30,000
Net sales								300,000
VYNE APA \| Amzeeq \| Fourth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								40,000
Net sales								400,000
VYNE APA \| Amzeeq \| Fifth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								50,000
Net sales								500,000
VYNE APA \| Zilxi \| First year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								10,000
Net sales								100,000
VYNE APA \| Zilxi \| Second year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								20,000
Net sales								200,000
VYNE APA \| Zilxi \| Third year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								30,000
Net sales								300,000
VYNE APA \| Zilxi \| Fourth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								40,000
Net sales								400,000
VYNE APA \| Zilxi \| Fifth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement								50,000
Net sales								$ 500,000